Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis

被引：4

作者：

Bili, Androniki ^{[1
]}

Morris, Stephanie J. ^{[1
]}

Sartorius, Jennifer A. ^{[1
]}

Kirchner, H. Les ^{[1
]}

Antohe, Jana L. ^{[1
]}

Dancea, Sorina ^{[1
]}

Wasko, Mary Chester ^{[1
]}

机构：

[1] Geisinger Hlth Syst, Dept Rheumatol, Danville, PA 17822 USA

来源：

JOURNAL OF RHEUMATOLOGY | 2012年 / 39卷 / 05期

关键词：

RHEUMATOID ARTHRITIS; LIPIDS; TUMOR NECROSIS FACTOR-alpha INHIBITORS; INFLIXIMAB TREATMENT; INSULIN-RESISTANCE; PROFILE; THERAPY; PATTERNS;

D O I：

10.3899/jrheum.111093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To determine the association of use of tumor necrosis factor-alpha (TNF-alpha) inhibitors with differences in lipid levels in patients with rheumatoid arthritis (RA). Methods. We studied 807 patients with incident RA to compare differences in lipid levels in TNF-alpha inhibitor users versus nonusers, with adjustment for relevant covariables. Results. TNF-alpha inhibitor use was not associated with differences in levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), triglycerides, LDL:HDL, or TC:HDL compared to nonusers. Conclusion. Use of TNF-alpha inhibitor was not associated with differences in lipid levels in patients with RA. (First Release April 1 2012; J Rheumatol 2012;39:946-8; doi:10.3899/jrheum.111093)

引用

页码：946 / 948

页数：3

共 50 条

[1] Current tumor necrosis factor-α inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis
Liang, GC
Cordero, M
Dyer, A
Chang, RW
JOURNAL OF RHEUMATOLOGY, 2005, 32 (09) : 1662 - 1665
[2] Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis
Asahina, Akihiko
Ishii, Norihisa
Tohma, Shigeto
JOURNAL OF DERMATOLOGY, 2012, 39 (02) : 199 - 201
[3] Tumor necrosis factor inhibitor therapy for rheumatoid arthritis
Naguwa, SM
AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 709 - 715
[4] Golimumab: A Tumor Necrosis Factor Alpha Inhibitor for the Treatment of Rheumatoid Arthritis
McCluggage, Lauren K.
Scholtz, Jean M.
ANNALS OF PHARMACOTHERAPY, 2010, 44 (01) : 135 - 144
[5] Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy
Curtis, Jeffrey R.
John, Ani
Baser, Onur
ARTHRITIS CARE & RESEARCH, 2012, 64 (09) : 1282 - 1291
[6] Tumor necrosis factor-α inhibitor associated ulcerative colitis
Prescott, Kara
Costner, Melissa
Cohen, Stanley
Kazi, Salahuddin
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 333 (03) : 137 - 139
[7] Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure
Yu, Amy W.
Pecsok, Maggie
Longbrake, Erin E.
Wesley, Sarah F.
NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (04) : E488 - E496
[8] Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis
Yazici, Yusuf
Krasnokutsky, Svetlana
Barnes, Jaime P.
Hines, Patricia L.
Wang, Jason
Rosenblatt, Lisa
JOURNAL OF RHEUMATOLOGY, 2009, 36 (05) : 907 - 913
[9] Systematic Review of Tumor Necrosis Factor Inhibitor Discontinuation Studies in Rheumatoid Arthritis
Navarro-Millan, Iris
Sattui, Sebastian E.
Curtis, Jeffrey R.
CLINICAL THERAPEUTICS, 2013, 35 (11) : 1850 - 1861
[10] Polymorphism in the tumor necrosis factor-α gene promoter is associated with severity of rheumatoid arthritis in the Czech population
Petr Nemec
Monika Pavkova-Goldbergova
Martina Stouracova
Anna Vasku
Miroslav Soucek
Jindra Gatterova
Clinical Rheumatology, 2008, 27 : 59 - 65

← 1 2 3 4 5 →